Description
Forxiga Coated Tablets 10 mg. №30
Ingredients
Each tablet contains 10 mg of dapagliflozin.
Mechanism of Action
Dapagliflozin, the active ingredient in Forxiga, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine.
Pharmacological Properties
Dapagliflozin acts by promoting the excretion of glucose through the urine, thereby lowering blood glucose levels in patients with type 2 diabetes mellitus.
Indications for Use
Forxiga tablets are indicated for the treatment of type 2 diabetes mellitus.
Contraindications
Forxiga should not be used in patients with severe renal impairment, end-stage renal disease, or patients on dialysis.
Side Effects
Common side effects of Forxiga may include genital mycotic infections. Regular monitoring of renal function is essential, particularly in patients with impaired renal function.
Usage Instructions
The recommended dosage of Forxiga is one 10 mg tablet taken orally once daily. It is crucial to follow the prescribed dose and consult a healthcare provider before making any changes.
Benefits Compared to Analogues
Studies have shown that dapagliflozin, the active ingredient in Forxiga, can significantly improve glycemic control and reduce body weight in patients with type 2 diabetes when used alone or in combination with other antidiabetic agents. Furthermore, dapagliflozin has been associated with a decreased risk of cardiovascular events in diabetic patients.
Suitable Patient Groups
Forxiga is suitable for adult patients with type 2 diabetes mellitus. However, caution should be exercised in patients with impaired renal function.
Storage and Shelf Life
Store Forxiga tablets in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product after the specified date.
Packaging Description
Forxiga is available in blister packs containing 30 coated tablets, with each tablet containing 10 mg of dapagliflozin.
Clinical Evidence and Proven Effectiveness
Clinical studies have demonstrated the efficacy of dapagliflozin in improving glycemic control and reducing body weight in patients with type 2 diabetes. Research published in the New England Journal of Medicine indicates that dapagliflozin, either as monotherapy or in combination with other antidiabetic agents, can lower hemoglobin A1c levels and reduce the risk of cardiovascular events in diabetic patients.
